Citations 1
ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
Reiter, Andreas , Bharathy, Savita, Iommazzo, Dana, Stalbovskaya, Viktoriya, Gopalakrishna, Prashanth, Passamonti, Francesco , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mesa, Ruben A.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7080-TPS7080
